New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

GAVRETO (pralsetinib) capsules

This specialty medication is authorized and manufactured internationally and is not registered or commercially distributed for retail sale in India. To verify patient eligibility, check international supply availability, or understand the regulatory logistics and documentation process: Call our Compliance Desk at 9891296838 or Email your Inquiry query@southdelhipharma.com.

Gavreto (pralsetinib) is a targeted prescription cancer medication used to treat specific advanced cancers driven by abnormal RET (rearranged during transfection) genes.

Brand Name: GAVRETO – On Request
Generic Name: pralsetinib
Strength: Capsules: 100 mg
Manufacturer: Blueprint Medicines Corporation
Approved By: EMA, USFDA
Get access to medicines: In India
Price: On Request

See full prescribing information for GAVRETO: Patient Information

Is GAVRETO (pralsetinib) officially available/approved in India?

No, as of now, GAVRETO (pralsetinib) is not officially marketed or registered for sale in India. It is mainly accessed in India through a Named Patient Program (NPP), which allows for the legal importation of the medication for patients with a valid prescription from the Registered Medical Practitioner (RMP). For sourcing facilitation services contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or  you can Call/WhatsApp at 9891296838.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

South Delhi Pharma is dedicated to facilitating access to critical, globally approved pharmaceutical therapies tailored to individual patient needs. Established in 1996, It has built a trusted reputation for assisting patients and healthcare institutions in navigating the regulatory frameworks required to securely source high-quality, international life-saving medications.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

This is an inquiry and facilitation request form. Submission does not constitute a sale, purchase order, or guarantee of medicine availability.

Description

Pralsetinib, sold under the brand name Gavreto, is a medication approve for RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy. Pralsetinib is a tyrosine kinase inhibitor.

The most common adverse reactions include increased aspartate aminotransferase (AST), decreased hemoglobin, decreased lymphocytes, decreased neutrophils, increased alanine aminotransferase (ALT), increased creatinine, increased alkaline phosphatase, fatigue, constipation, musculoskeletal pain, decreased calcium, hypertension, decreased sodium, decreased phosphate, and decreased platelets.

GAVRETO (pralsetinib) capsules, for oral use Initial U.S. Approval: 2020

Get Assistance for GAVRETO Import

Need urgent access to GAVRETO? We’re here to help.

  • Expert support for documentation & approvals
  • Fast-track import coordination
  • End-to-end patient assistance

Call Now | Enquire Today | WhatsApp Support Available

Contact Sourcing Facilitation Team

Contact Name: Mr. Tarun Garg
Address: 60/4, Yusaf Sarai, Near Indian Oil Corp., New Delhi – 110 016 (India)
Mobile/WhatsApp. 9891296838.
Email: support@southdelhipharma.com, southdelhipharma@gmail.com

NEWS / UPDATES

Get Access To GAVRETO (pralsetinib) In India

In India, access is facilitated through a legally compliant Named Patient Program (NPP), as per guidelines from the Central Drugs Standard Control Organization. This ensures safe and regulated import of the medicine for individual patients. Brand Name “GAVRETO” or Generic Name “pralsetinib” can be imported for personal use under “Named Patient Program” treatment in in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla India.. Contact us at support@southdelhipharma.com, southdelhipharma@gmail.com or call/WhatsApp at +91-9891296838 to get access as per norms.

Note: South Delhi Pharma, act as a facilitation partner and do not manufacture, sell, or distribute pharmaceutical products. All facilitation activities are conducted in accordance with applicable Indian pharmaceutical and trade regulations. 

Related Products